When was CASI Pharmaceuticals founded?

CASI Pharmaceuticals was founded in 1991 and raised its 1st funding round 15 years after it was founded.

Where is CASI Pharmaceuticals located?

CASI Pharmaceuticals is headquartered in Rockville, United States.

Who is the current CEO of CASI Pharmaceuticals?

Ken Ren of CASI Pharmaceuticals.

How many employees does CASI Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at CASI Pharmaceuticals is 42.

Is CASI Pharmaceuticals a funded company?

CASI Pharmaceuticals is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on 2006.

When was the latest funding round of CASI Pharmaceuticals?

CASI Pharmaceuticals' latest funding was a $***** Post IPO round on Dec 27, 2025, with participation from 0 investor.

What is the annual revenue of CASI Pharmaceuticals?

Annual revenue of CASI Pharmaceuticals is between $10M and $50M as on Dec 31, 2021

Where does CASI Pharmaceuticals rank among its competitors?

CASI Pharmaceuticals ranks 90th amongst 3264 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of CASI Pharmaceuticals?

CASI Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

CASI Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of cancer. The company's pipeline includes ENMD-2076, a selective angiogenic kinase inhibitor, and 2ME2 for autoimmune disorders. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma.

Key Metrics

Founded Year

1991

Location

Rockville, United States

Stage

Public

Latest Funding Round

Post IPO, Dec 27, 2025, $*****

Investors

Accel & 5 more

Ranked

90^th among 3264 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2021

Employee Count

42 as on Jun 30, 2026

Investment & Acquisitions

Beijing Tianshi Tongda Pharmaceutical Technology & 2 more

Similar Companies

Jazz Pharmaceuticals & 2974 more

Exit Details

Public

View CASI Pharmaceuticals' full profile

CASI Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Entremed Inc CIN: 895051 , United States, Active		$0 - $1M (As on Dec 31, 2012)	-	-
CASI Pharmaceuticals Inc. CIN: 58-1959440 , United States, Active	Dec 31, 1990	-	224 (As on Dec 31, 2022)	-
CASI PHARMACEUTICALS, INC. CIN: 895051 , United States, Active	Sep 17, 1991	$10M - $50M (As on Dec 31, 2021)	10 (As on Dec 31, 2022)	-

CASI Pharmaceuticals got listed on Jun 11, 1996.

Click here to take a look at CASI Pharmaceuticals's IPO in detail

CASI Pharmaceuticals has raised funding over 5 rounds. Its first funding round was on 2006. CASI Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of CASI Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 27, 2025	7604642	Post IPO	8421262	9915945	7581102	3533292
Jun 26, 2024	3153648	Post IPO	9409650	9011043	5484627	4959650
Jan 19, 2016	8556867	Post IPO	1419199	6084444	7136215	IDG Capital

Access funding benchmarks and valuations. Sign up today!

View details of CASI Pharmaceuticals's funding rounds and investors

CASI Pharmaceuticals' employee count trend

CASI Pharmaceuticals has 42 employees as of Jun 26. Here is CASI Pharmaceuticals's employee count trend over the years:

Employee count trend for CASI Pharmaceuticals

Uncover CASI Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CASI Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of CASI Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
90th	CASI Pharmaceuticals 1991, Rockville (United States), Public	Developer of therapeutics for the treatment of cancer	-	Accel, Aravis & 4 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on CASI Pharmaceuticals's competitors? Click here to see the top ones

CASI Pharmaceuticals has made 3 investments including Beijing Tianshi Tongda Pharmaceutical Technology, Juventas Therapeutics and Heyuan Biotechnology. CASI Pharmaceuticals has not made any acquisitions as of now.

Here is the list of its investments:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jul 05, 2022	Investments	Beijing Tianshi Tongda Pharmaceutical Technology	2022	Beijing (China)
Oct 25, 2021	Investments	Juventas Therapeutics	2007	Cleveland (United States)
Jul 09, 2019	Investments	Heyuan Biotechnology	2018	Chaoyang (China)

Want to know more about where corporates are investing? Sign up today!

See all investments by CASI Pharmaceuticals

Here is the latest report on CASI Pharmaceuticals's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to CASI Pharmaceuticals

Media has covered CASI Pharmaceuticals for a total of 16 events in the last 1 year, 7 of them have been about company updates and 3 about people movement.